Introduction
The United States FDA regulates pharma drug products manufactured or marketed in the United States. There are many different functions of the FDA, and one of them is devising new regulations. These new regulations come into existence in response to various factors, such as
· Feedback from different stakeholders
· Complains
· Innovation & development in the pharma industry.
For continuous operations, it is necessary for every pharma manufacturer to comply with these regulations They can face warning, fines or even shutting down of their operations in an event of non-compliance.
These regulations are made available on its website for public view.
Some guidance documents in the year 2024
Let’s take a brief overview of the regulations made in the year – 2024
Advanced Manufacturing Technologies Designation Program
This guidance is about advanced manufacturing technologies in the pharma industry. The FDA acknowledges the importance of these technologies towards the reliability of the process, product quality, and reduction of development time, especially for life-supporting drugs.
This guidance provides recommendations for individuals or organizations to participate in the FDA’s Advanced Manufacturing Technologies Designation Program, which facilitates the implementation of TMA.
M15 General Principles for Model-Informed Drug Development
This FDA guidance provides guidelines related to Model Informed Drug Development – MIDD. This development program uses different quantitative methods to reduce risks during the development program.
This guidance is prepared under the auspices of ICH and discusses different areas of MIDD, such as planning, model evaluation and evidence documentation.
E11A Pediatric Extrapolation
This guidance is also prepared under the auspices of ICH and focuses on pediatric extrapolation during drug development. It contains approaches to study design and statistical methodologies, such as modelling & simulation.
This guidance intends to increase the efficiency of pediatric drug development and enhance safe & effective pediatric drug availability.
Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices
This guidance is intended for sponsors, clinical investigators, and institutional review boards to define, identify, and report protocol deviation during clinical investigation.
It includes definition of protocol deviation, recommendations for sponsors to report deviations to the FDA, types of deviations that investigators should report to sponsors & IRBs, and for IRBs when evaluating protocol deviation
Accelerated Approval – Expedited Program for Serious Conditions
The purpose of these guidelines is to help provide FDA policies about accelerated approval, which is an expedited program of the FDA to facilitate the development of new drugs with high and urgent needs.
This guidance also covers the expedited withdrawal of a product approved under an accelerated approval program and revisions Congress made through the Consolidated Appropriations Act, 2023 (Public Law 117-328)
Requests for Reconsideration at the Division Level Under GDUFA
This guidance provides guidance related to the applicants of abbreviated new drug applications (ANDAs) who wish to pursue reconciliation within the review discipline at the division level or original signatory authority.
Temporary Policies for Compounding Certain Parenteral Drug Products
This guideline describes the FDA's thinking on compounding certain parenteral drug products by outsourcing facilities, State-licensed pharmacies, and non–registered outsourcing FDA Federal facilities.
Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers
This guidance is for sponsors, clinical investigators, contract ...
(All Rights Reserved)